Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence

Wiebke Pruessmann, Julie Rytlewski, James Wilmott, Martin C Mihm, Grace H Attrill, Beatrice Dyring-Andersen, Paul Fields, Qian Zhan, Andrew J Colebatch, Peter M Ferguson, John F Thompson, Klaus Kallenbach, Erik Yusko, Rachael A Clark, Harlan Robins, Richard A Scolyer, Thomas S Kupper*

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftArtikelForskningpeer review


Primary melanomas >1 mm thickness are potentially curable by resection, but can recur metastatically. We assessed the prognostic value of T cell fraction (TCFr) and repertoire T cell clonality, measured by high-throughput-sequencing of the T cell receptor beta chain (TRB) in T2-T4 primary melanomas (n=199). TCFr accurately predicted progression-free survival (PFS) and was independent of thickness, ulceration, mitotic rate, or age. TCFr was second only to tumor thickness in its predictive value, using a gradient boosted model. For accurate PFS prediction, adding TCFr to tumor thickness was superior to adding any other histopathological variable. Furthermore, a TCFr >20% was protective regardless of tumor ulceration status, mitotic rate or presence of nodal disease. TCFr is a quantitative molecular assessment that predicts metastatic recurrence in primary melanoma patients whose disease has been resected surgically. This study suggests that a successful T cell-mediated antitumor response can be present in primary melanomas.

Sider (fra-til)197-209
Antal sider13
TidsskriftNature Cancer
Udgave nummer2
StatusUdgivet - feb. 2020


Udforsk hvilke forskningsemner 'Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence' indeholder.